EPA alleged that DuPont repeatedly failed to report information about substantial risks associated with PFOA, a chemical used in manufacturing some fluoropolymers. The information dated as far back as 1981 and concerned human exposure, environmental contamination, and animal studies.
In 2005, DuPont agreed to a $10.25 million civil administrative penalty and $6.25 million in environmental projects. A later GAO report describes blood-test results regulators received from lawsuit counsel rather than DuPont. The settlement is documented, but DuPont did not admit that it should have reported the biomonitoring data. This was a reporting-case settlement, not a criminal conviction.
The reporting dispute turns on information flow. A regulator cannot evaluate a risk fully if material exposure and study information stays inside a manufacturer or reaches the agency by a different route. The case asks what the company was required to report and when.
The enforcement record should not be inflated into a different legal outcome. The 2005 agreement was a civil administrative settlement, with disputed reporting duties and no admission concerning the biomonitoring data. The distinction preserves the strength of the documented case while avoiding an invented criminal conviction.
The established record.
- 01
EPA brought claims concerning unreported PFOA risk information.
- 02
The 2005 settlement included a $10.25 million penalty.
- 03
DuPont also committed $6.25 million to environmental projects.
How the story unfolded.
- 1981 onwards
Risk information accumulates
EPA’s allegations concern material dating back to the early 1980s.
- 2005
A reporting-case settlement
DuPont agrees to a penalty and environmental projects.
- Later review
The information trail is examined
GAO describes regulators receiving blood-test results through lawsuit counsel.
Where the evidence stops.
A settlement is not an admission of all allegations. The fine alone was $10.25 million; exposure data alone do not prove illness.
Read the original sources.
The source may establish a narrower point than the headline. Follow the specific finding, its date and its limitations.
What happens when the people assessing a risk do not receive the information held by its producer?